Alembic Pharmaceuticals Ltd (APLLTD) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Alembic Pharmaceuticals Ltd on NSE and BSE, with an AI summary of each filing.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC).
Press Release · 05 Nov 2026, 3:26 am
Alembic Pharmaceuticals Receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution Alembic Pharmaceuticals has secured USFDA final approval for its ANDA Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), therapeutically equivalent to Alcon’s Pataday Once Daily Relief. Developed with Orbicular Pharmaceutical Technologies, the product targets itchy eyes relief, addressing an estimated US market size of US$20 million for the 12 months ending Sep'26. This approval increases Alembic’s cumulative USFDA tally to 248 ANDA approvals, comprising 229 final approvals and 19 tentative approvals.
Please find attached Audio Recording of Investor Call.
Audio / Video · 05 Nov 2026, 12:30 am
Alembic Pharmaceuticals Hosts Post-Results Earnings Call Audio Recording Alembic Pharmaceuticals has informed stock exchanges that the audio recording of its post-results conference call held on 4th Nov'26 is available on the company's official website. Investors and market participants can access the recording directly via the quarterly results section at alembicpharmaceuticals.com/quarterly-results.
Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015.
Others (Uncategorized) · 04 Nov 2026, 8:41 pm
Alembic Pharma Updates Authorized Personnel for SEBI Material Disclosures Alembic Pharmaceuticals Limited’s Board has updated authorized Key Managerial Personnel contact details under SEBI Listing Regulations, effective 4th Nov'26. Executive Chairman Chirayu Amin, Managing Directors Pranav Amin and Shaunak Amin, and CFO G. Krishnan are authorized to determine event materiality and make stock exchange disclosures. Company Secretary Chirag K. Shukla is authorized to make regulatory disclosures. All personnel are reachable via contact number 0265 6637000.
Please find attached Press Release
Press Release · 04 Nov 2026, 8:10 pm
Alembic Expands Strategic DifGen Tie-Up for US Complex Generics Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize a portfolio of 20+ differentiated complex generics in the US, targeting an aggregate reference market of ~$5 billion across injectable, transdermal, ophthalmic, and oral dosage forms. DifGen will manage development, regulatory, and US manufacturing, while Alembic will handle US commercialization and select manufacturing. The pipeline includes open First-to-File (FTF) assets and potential Day-1 launches with limited competition. Initial commercial launches are slated to commence from FY28, granting Alembic reserved US manufacturing capacity.
Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026.
Investor Presentation · 04 Nov 2026, 8:08 pm
Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth Alembic Pharmaceuticals delivered strong Q2 FY27 performance, with revenue growing 36% YoY to ₹26.03 bn, driven by double-digit expansion across all segments: US formulations surged 77% YoY to ₹10.03 bn, API grew 39% to ₹4.36 bn, India branded rose 14% to ₹7.25 bn, and Ex-US climbed 12% to ₹4.40 bn. EBITDA surged 78% YoY to ₹5.78 bn as EBITDA margins expanded 520 bps to 22%, while PAT attributable to shareholders jumped 81% YoY to ₹3.35 bn. R&D spend stood at 8% of revenue.
Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026.
Press Release · 04 Nov 2026, 8:04 pm
Alembic Pharmaceuticals Reports Robust Q2 FY27 Results with 81% PAT Growth Alembic Pharmaceuticals reported a strong performance for Q2 FY27 ended 30th Sep'26, with consolidated revenue rising 36% YoY to Rs 2,603 Cr. EBITDA grew 78% YoY to Rs 578 Cr with a 22% margin, while PAT jumped 81% YoY to Rs 335 Cr. Growth was driven by US Formulations, which surged 77% YoY to Rs 1,003 Cr backed by three new launches. API revenue expanded 39% YoY to Rs 436 Cr, India Formulations grew 14% to Rs 725 Cr, and Ex-US rose 12% to Rs 440 Cr.
Please find attached Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026.
Financial Result · 04 Nov 2026, 8:01 pm
Alembic Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on November 04, 2026.
Outcome · 04 Nov 2026, 7:59 pm
Alembic Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 04 Nov 2026, 7:57 pm
Please find attached Unaudited Financial Results for the Quarter and Half Year ended 30th September, 2026.
Outcome · 04 Nov 2026, 7:56 pm
Alembic Pharmaceuticals Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 2,603 (+36.3% YoY | +21.1% QoQ) ■ EBITDA: 563 (+78.4% YoY | +69.7% QoQ) ■ EBITDA Margin (%): 21.6 (+511 bps YoY | +620 bps QoQ) ■ PAT: 335 (+81.5% YoY | +93.7% QoQ) ■ EPS (INR): 17.1 (+81.4% YoY | +93.7% QoQ)
Updated link for the Post Results Conference Call
Intimation · 04 Nov 2026, 5:00 pm
Alembic Pharmaceuticals Updates Registration Link for Upcoming Post-Results Earnings Call Alembic Pharmaceuticals has issued an updated registration link for its post-results conference call with analysts and institutional investors, scheduled for 4th Nov'26 at 5:00 PM IST. Dial-in details remain unchanged, with universal access available at +91 22 6280 1411 and +91 22 7115 8312, alongside international toll-free options for the USA, UK, Singapore, and Hong Kong.
Please find enclosed intimation for Investor Call re-scheduled on 4th November, 2026.
Intimation · 04 Nov 2026, 5:00 pm
Alembic Pharmaceuticals Reschedules Q2 FY27 Earnings Call to 4th Nov'26 Alembic Pharmaceuticals Limited has rescheduled its post-results conference call for analysts and institutional investors to discuss its Q2 FY27 unaudited financial results. The call is now set for 4th Nov'26 at 5:00 PM IST with the senior management team. Participants can join via pre-registration through Diamond Pass or via universal dial-in numbers (+91 22 6280 1411 / +91 22 7115 8312) alongside international toll-free options for the USA, UK, Singapore, and Hong Kong.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Venetoclax Tablets, 10mg, 50 mg and 100 mg.
Press Release · 30 Oct 2026, 11:59 pm
Alembic Pharmaceuticals Receives USFDA Approval for Generic Venclexta With 180-Day Exclusivity Eligibility Alembic Pharmaceuticals received USFDA final approval on 30th Oct'26 for its ANDA for Venetoclax Tablets (10 mg, 50 mg, and 100 mg), generic to AbbVie's Venclexta. As a first-to-file Paragraph IV applicant, Alembic may be eligible for 180 days of generic exclusivity. The product addresses CLL, SLL, and AML indications, targeting an estimated US market size of US $1,584 million for the twelve months ending Jun'26. Alembic now holds a cumulative total of 248 USFDA ANDA approvals, comprising 228 final and 20 tentative approvals.
Please find enclosed Intimation for Investor Call scheduled to be held on 4th November, 2026.
Intimation · 04 Nov 2026, 4:00 pm
Alembic Pharmaceuticals Schedules Q2 FY27 Post-Results Earnings Conference Call Alembic Pharmaceuticals Limited will host an earnings conference call with its senior management team for analysts and institutional investors on 4th Nov'26 at 4:00 PM IST to discuss its unaudited financial results for Q2 FY27. Participants can join through pre-registration or access the call via universal dial-in numbers (+91 22 6280 1411 / +91 22 7115 8312) alongside international toll-free lines for the USA, UK, Singapore, and Hong Kong.
Alembic Pharmaceuticals Limited has informed the Exchange about Board Meeting to be held on 04-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 04 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 04 Nov 2026, 5:30 am
Alembic Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve Unaudited Financial ....
Intimation · 04 Nov 2026, 5:30 am
Alembic Pharmaceuticals Schedules Board Meeting to Approve Q2 and H1 FY27 Results Alembic Pharmaceuticals Limited announced that its Board of Directors will meet on 4th Nov'26 to consider and approve the unaudited financial results for the quarter and half-year ended 30th Sep'26. In compliance with the company's insider trading code of conduct, the trading window for dealing in company securities, which closed on 1st Oct'26, will reopen 48 hours after the declaration of the financial results.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Valganciclovir for Oral Solution, 50 mg/mL.
Press Release · 27 Oct 2026, 8:59 pm
Alembic Pharma Receives USFDA Final Approval for Valganciclovir Oral Solution Alembic Pharmaceuticals secured final USFDA approval for its ANDA for Valganciclovir for Oral Solution, 50 mg/mL, on 27th Oct'26. The product is therapeutically equivalent to the RLD, Valcyte for Oral Solution (50 mg/mL) by CHEPLAPHARM Arzneimittel GmbH. The drug is indicated for treating CMV retinitis in AIDS patients and preventing CMV disease in high-risk kidney, heart, or kidney-pancreas transplant recipients. With this clearance, Alembic's cumulative USFDA approvals reach 247 ANDAs, comprising 227 final approvals and 20 tentative approvals.
Please find attached herewith the Intimation under Regulation 30 of SEBI LODR Regulations, 2015
Others (Uncategorized) · 20 Oct 2026, 12:50 am
Alembic Pharmaceuticals Incorporates Step-Down Subsidiary Alvesta Pharmaceuticals in UAE Alembic Pharmaceuticals' wholly owned subsidiary, Alembic Global Holding SA, incorporated a step-down wholly owned subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai, UAE, on 1st Sep'26. The new entity was formed via cash consideration of AED 100,000, comprising 100 shares at AED 1,000 each, giving Alembic 100% control. The entity will operate in the pharmaceutical industry to explore new business opportunities and manage the promotion, sale, and distribution of the company’s pharmaceutical products.
Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP 0.3% / 0.1%
Press Release · 18 Oct 2026, 12:22 am
Alembic Pharmaceuticals Secures USFDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension Alembic Pharmaceuticals received USFDA final approval on 17th Oct'26 for its ANDA Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%, therapeutically equivalent to Sandoz Inc.'s Ciprodex. The product is indicated for acute otitis media and acute otitis externa. Per IQVIA data, the product's estimated market size was US$110mn for the 12 months ending Jun'26. With this nod, Alembic holds a cumulative total of 246 USFDA ANDA approvals, comprising 226 final and 20 tentative approvals.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for DSP Trustee Pvt Ltd & Others
Acquisition/ Disposal of Shares · 29 Sept 2026, 5:02 pm
DSP Entities Trim Stake in Alembic Pharma via Open Market Sale DSP Trustee Pvt Ltd and PACs trimmed their combined stake in Alembic Pharma Ltd to 2.97% (58,31,766 shares) from 3.04% (59,68,340 shares) following an open-market disposal of 1,36,574 equity shares (0.07% of paid-up capital) on 24th Sep'26. The sale was executed via DSP Mid Cap Fund and DSP India Equity Fund (ICAV), triggering a Regulation 29(2) disclosure as cumulative holding changes breached the 2% reporting threshold since previous disclosures. Total voting capital post-transaction stands at 19,65,63,124 shares (Rs 39.31 cr paid-up capital).
Please find enclosed Intimation of One to One Investor Meet.
Intimation · 18 Sept 2026, 10:58 pm
Alembic Pharmaceuticals Schedules One-on-One Institutional Investor Meetings in Mumbai Alembic Pharmaceuticals Limited announced that company officials will conduct one-on-one meetings with institutional investors and analysts in Mumbai on 23rd Sep'26, starting from 10:00 AM onwards. The discussions will strictly rely on publicly available information, and no unpublished price-sensitive information (UPSI) will be shared during the interactions. Meeting schedules remain subject to change based on exigencies from either party.
Update on USFDA inspection conducted during 3rd March, 2025 to 7th March, 2025 at Bioequivalence Facility located at Vadodara, Gujarat.
Others (Uncategorized) · 16 Sept 2026, 11:37 pm
Alembic Pharma Receives USFDA EIR for Vadodara Bioequivalence Facility Alembic Pharmaceuticals Limited announced that the US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR), successfully closing the inspection for its Bioequivalence Facility located at Vadodara, Gujarat. The regulatory audit was conducted between 3rd Mar'25 and 7th Mar'25. The receipt of the EIR confirms regulatory compliance and clears the facility of pending inspectional concerns.
Successful completion of unannounced USFDA onsite inspection at Alembic Pharmaceuticals Limited''s Bioequivalence Facility in Vadodara, Gujarat.
Others (Uncategorized) · 11 Sept 2026, 5:07 pm
Alembic Pharmaceuticals Clears USFDA Inspection at Vadodara Facility with Zero Observations Alembic Pharmaceuticals has successfully completed an unannounced onsite USFDA bioequivalence inspection at its facility in Vadodara, Gujarat, with zero Form 483 observations. The inspection was conducted from 31st Aug'26 to 10th Sep'26. The clean regulatory outcome eliminates immediate US compliance risks for the bioequivalence site, supporting the company's product development pipeline and regulatory approval timelines for the US market.
Please find enclosed herewith the Intimation regarding Incorporation of a wholly owned subsidiary company of the Company.
Others (Uncategorized) · 08 Sept 2026, 2:03 am
Alembic Pharmaceuticals Incorporates Wholly Owned Subsidiary in Dubai Alembic Pharmaceuticals has incorporated a wholly owned subsidiary, Alembic Pharmaceuticals Global FZCO, in Dubai, UAE, on 24th Aug'26. The entity has been established with a 100% shareholding via a cash subscription of AED 100,000, comprising 100 shares at AED 1,000 each. The new subsidiary will operate in the pharmaceutical sector, focusing on exploring new business opportunities alongside promoting, selling, and distributing the company's pharmaceutical products globally.